Jonathan R Brody
Overview
Explore the profile of Jonathan R Brody including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
5179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Habowski A, Budagavi D, Scherer S, Aurora A, Caligiuri G, Flynn W, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339316
For over a century, early researchers sought to study biological organisms in a laboratory setting, leading to the generation of both in vitro and in vivo model systems. Patient-derived models...
12.
Shah V, Rizvi S, Smith A, Tsuda M, Krieger M, Pelz C, et al.
Pharmaceutics
. 2023 Dec;
15(12).
PMID: 38139993
Pancreatic cancer remains a formidable challenge due to limited treatment options and its aggressive nature. In recent years, the naturally occurring anticancer compound juglone has emerged as a potential therapeutic...
13.
Golan T, Raitses-Gurevich M, Beller T, Carroll J, Brody J
Cancer Treat Res
. 2023 Nov;
186:125-142.
PMID: 37978134
A subset of patients with pancreatic adenocarcinomas (PDAC) harbor mutations that are exploitable in the context of DNA-damage response and repair (DDR) inhibitory strategies. Between 8-18% of PDACs harbor specific...
14.
Ponzini F, Schultz C, Leiby B, Cannaday S, Yeo T, Posey J, et al.
BMJ Open
. 2023 Oct;
13(10):e073839.
PMID: 37848297
Background: Recent reports of the utilisation of pyrvinium pamoate (PP), an FDA-approved anti-helminth, have shown that it inhibits pancreatic ductal adenocarcinoma (PDAC) cell growth and proliferation in-vitro and in-vivo in...
15.
Finan J, Sutton T, Dixon D, Brody J
Cancer Res
. 2023 Sep;
83(21):3507-3516.
PMID: 37683260
The RNA-binding protein human antigen R (HuR) is a well-established regulator of gene expression at the posttranscriptional level. Its dysregulation has been implicated in various human diseases, particularly cancer. In...
16.
Vaziri-Gohar A, Hue J, Abbas A, Graor H, Hajihassani O, Zarei M, et al.
Nat Commun
. 2023 Jun;
14(1):3823.
PMID: 37380658
Pancreatic Ductal Adenocarcinoma (PDAC) is highly resistant to chemotherapy. Effective alternative therapies have yet to emerge, as chemotherapy remains the best available systemic treatment. However, the discovery of safe and...
17.
McCarthy G, Di Niro R, Finan J, Jain A, Guo Y, Wyatt C, et al.
NAR Cancer
. 2023 Apr;
5(2):zcad016.
PMID: 37089813
Stromal cells promote extensive fibrosis in pancreatic ductal adenocarcinoma (PDAC), which is associated with poor prognosis and therapeutic resistance. We report here for the first time that loss of the...
18.
McCarthy G, Jain A, Di Niro R, Schultz C, Jiang W, Yeo C, et al.
Transl Oncol
. 2023 Apr;
32:101662.
PMID: 37004490
Introduction: Standard-of-care systemic chemotherapies for pancreatic ductal adenocarcinoma (PDAC) currently have limited clinical benefits, in addition to causing adverse side effects in many patients. One factor known to contribute to...
19.
Korzun T, Moses A, Kim J, Patel S, Schumann C, Levasseur P, et al.
Small
. 2022 Sep;
18(44):e2204436.
PMID: 36098251
This study presents the first messenger RNA (mRNA) therapy for metastatic ovarian cancer and cachexia-induced muscle wasting based on lipid nanoparticles that deliver follistatin (FST) mRNA predominantly to cancer clusters...
20.
Sutton T, Koprowski M, Gold J, Liu B, Grossblatt-Wait A, Macuiba C, et al.
J Natl Compr Canc Netw
. 2022 Jul;
20(7):765-773.e4.
PMID: 35830889
Background: Screening for cancer-related psychosocial distress is an integral yet laborious component of quality oncologic care. Automated preappointment screening through online patient portals (Portal, MyChart) is efficient compared with paper-based...